No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients

J. A. Scott, J. J. Arnold, Charles John Broadfoot, A. Graham, J. N. Kirkpatrick, Michael Greaves, J. M. Currie, M Davidson

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Factor V:Q506 ( factor V Leiden) is associated with venous thrombosis and has been reported to be a risk factor for retinal Vein occlusion (RVO), Anticardiolipin antibodies (ACA), also associated with RVO, are a marker for the prothrombotic condition antiphospholipid syndrome, in which antiendothelial antibodies (AECA) are also frequently present. This study reviewed 45 younger patients less than or equal to 55 years old (21 with branch, 22 with central and 2 with hemispheric RVO) to examine: (1) the role of factor V:Q506 in the pathogenesis of RVO, and (2) the prevalence and titre of ACA and AECA in this group. No patient had the factor V:Q506 mutation indicating no increase in frequency above background. Our data suggest that primary screening for factor V:Q506 is not indicated for young patients with RVO who do not have historical evidence suggesting familial thrombophilia. Twenty-nine patients had low-titre ACA (> 10 GPL units); in 6 of these, the titre was > 20 GPL units (population reference range = 0-10 GPL units). No patient had antiendothelial cell reactivity. The low-titre ACA may therefore represent a non specific response to vascular injury. Copright (C) 2001 S.Karger AG, Basel.

Original languageEnglish
Pages (from-to)217-221
Number of pages4
JournalOphthalmologica
Volume215
Issue number3
DOIs
Publication statusPublished - 2001

Keywords

  • retinal vein occlusion
  • factor V : Q506
  • factor V Leiden
  • antiphospholipid syndrome
  • antiendothelial cell antibody
  • protein C
  • activated protein C resistance
  • ACTIVATED PROTEIN-C
  • PRIMARY ANTIPHOSPHOLIPID SYNDROME
  • FACTOR-V-LEIDEN
  • VENOUS THROMBOSIS
  • VASOOCCLUSIVE RETINOPATHY
  • ARTERIAL-OCCLUSION
  • VASCULAR-DISEASE
  • RISK FACTOR
  • RESISTANCE
  • GENE

Cite this

No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients. / Scott, J. A.; Arnold, J. J.; Broadfoot, Charles John; Graham, A.; Kirkpatrick, J. N.; Greaves, Michael; Currie, J. M.; Davidson, M .

In: Ophthalmologica, Vol. 215, No. 3, 2001, p. 217-221.

Research output: Contribution to journalArticle

Scott, JA, Arnold, JJ, Broadfoot, CJ, Graham, A, Kirkpatrick, JN, Greaves, M, Currie, JM & Davidson, M 2001, 'No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients', Ophthalmologica, vol. 215, no. 3, pp. 217-221. https://doi.org/10.1159/000050862
Scott, J. A. ; Arnold, J. J. ; Broadfoot, Charles John ; Graham, A. ; Kirkpatrick, J. N. ; Greaves, Michael ; Currie, J. M. ; Davidson, M . / No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients. In: Ophthalmologica. 2001 ; Vol. 215, No. 3. pp. 217-221.
@article{3c152f3f45b74105aa4c05d62d5fd2d8,
title = "No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients",
abstract = "Factor V:Q506 ( factor V Leiden) is associated with venous thrombosis and has been reported to be a risk factor for retinal Vein occlusion (RVO), Anticardiolipin antibodies (ACA), also associated with RVO, are a marker for the prothrombotic condition antiphospholipid syndrome, in which antiendothelial antibodies (AECA) are also frequently present. This study reviewed 45 younger patients less than or equal to 55 years old (21 with branch, 22 with central and 2 with hemispheric RVO) to examine: (1) the role of factor V:Q506 in the pathogenesis of RVO, and (2) the prevalence and titre of ACA and AECA in this group. No patient had the factor V:Q506 mutation indicating no increase in frequency above background. Our data suggest that primary screening for factor V:Q506 is not indicated for young patients with RVO who do not have historical evidence suggesting familial thrombophilia. Twenty-nine patients had low-titre ACA (> 10 GPL units); in 6 of these, the titre was > 20 GPL units (population reference range = 0-10 GPL units). No patient had antiendothelial cell reactivity. The low-titre ACA may therefore represent a non specific response to vascular injury. Copright (C) 2001 S.Karger AG, Basel.",
keywords = "retinal vein occlusion, factor V : Q506, factor V Leiden, antiphospholipid syndrome, antiendothelial cell antibody, protein C, activated protein C resistance, ACTIVATED PROTEIN-C, PRIMARY ANTIPHOSPHOLIPID SYNDROME, FACTOR-V-LEIDEN, VENOUS THROMBOSIS, VASOOCCLUSIVE RETINOPATHY, ARTERIAL-OCCLUSION, VASCULAR-DISEASE, RISK FACTOR, RESISTANCE, GENE",
author = "Scott, {J. A.} and Arnold, {J. J.} and Broadfoot, {Charles John} and A. Graham and Kirkpatrick, {J. N.} and Michael Greaves and Currie, {J. M.} and M Davidson",
year = "2001",
doi = "10.1159/000050862",
language = "English",
volume = "215",
pages = "217--221",
journal = "Ophthalmologica",
issn = "0030-3755",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients

AU - Scott, J. A.

AU - Arnold, J. J.

AU - Broadfoot, Charles John

AU - Graham, A.

AU - Kirkpatrick, J. N.

AU - Greaves, Michael

AU - Currie, J. M.

AU - Davidson, M

PY - 2001

Y1 - 2001

N2 - Factor V:Q506 ( factor V Leiden) is associated with venous thrombosis and has been reported to be a risk factor for retinal Vein occlusion (RVO), Anticardiolipin antibodies (ACA), also associated with RVO, are a marker for the prothrombotic condition antiphospholipid syndrome, in which antiendothelial antibodies (AECA) are also frequently present. This study reviewed 45 younger patients less than or equal to 55 years old (21 with branch, 22 with central and 2 with hemispheric RVO) to examine: (1) the role of factor V:Q506 in the pathogenesis of RVO, and (2) the prevalence and titre of ACA and AECA in this group. No patient had the factor V:Q506 mutation indicating no increase in frequency above background. Our data suggest that primary screening for factor V:Q506 is not indicated for young patients with RVO who do not have historical evidence suggesting familial thrombophilia. Twenty-nine patients had low-titre ACA (> 10 GPL units); in 6 of these, the titre was > 20 GPL units (population reference range = 0-10 GPL units). No patient had antiendothelial cell reactivity. The low-titre ACA may therefore represent a non specific response to vascular injury. Copright (C) 2001 S.Karger AG, Basel.

AB - Factor V:Q506 ( factor V Leiden) is associated with venous thrombosis and has been reported to be a risk factor for retinal Vein occlusion (RVO), Anticardiolipin antibodies (ACA), also associated with RVO, are a marker for the prothrombotic condition antiphospholipid syndrome, in which antiendothelial antibodies (AECA) are also frequently present. This study reviewed 45 younger patients less than or equal to 55 years old (21 with branch, 22 with central and 2 with hemispheric RVO) to examine: (1) the role of factor V:Q506 in the pathogenesis of RVO, and (2) the prevalence and titre of ACA and AECA in this group. No patient had the factor V:Q506 mutation indicating no increase in frequency above background. Our data suggest that primary screening for factor V:Q506 is not indicated for young patients with RVO who do not have historical evidence suggesting familial thrombophilia. Twenty-nine patients had low-titre ACA (> 10 GPL units); in 6 of these, the titre was > 20 GPL units (population reference range = 0-10 GPL units). No patient had antiendothelial cell reactivity. The low-titre ACA may therefore represent a non specific response to vascular injury. Copright (C) 2001 S.Karger AG, Basel.

KW - retinal vein occlusion

KW - factor V : Q506

KW - factor V Leiden

KW - antiphospholipid syndrome

KW - antiendothelial cell antibody

KW - protein C

KW - activated protein C resistance

KW - ACTIVATED PROTEIN-C

KW - PRIMARY ANTIPHOSPHOLIPID SYNDROME

KW - FACTOR-V-LEIDEN

KW - VENOUS THROMBOSIS

KW - VASOOCCLUSIVE RETINOPATHY

KW - ARTERIAL-OCCLUSION

KW - VASCULAR-DISEASE

KW - RISK FACTOR

KW - RESISTANCE

KW - GENE

U2 - 10.1159/000050862

DO - 10.1159/000050862

M3 - Article

VL - 215

SP - 217

EP - 221

JO - Ophthalmologica

JF - Ophthalmologica

SN - 0030-3755

IS - 3

ER -